The number of conditions where IKKβ inhibitors are being pursued as a treatment option was too great to cover here but includes: obesity-associated metabolic disease [253], atherosclerosis [254], multiple sclerosis [255], COPD [256], muscular dystrophy [257], Parkinson’s disease [258], inflammatory bowel disease [259] and chronic arthritis [260]. The gene discussed is IKBKB; the disease is chronic obstructive pulmonary disease.